SEC Form 4 · accession 0001104659-17-019006
Mylan N.V. · MYL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, nominal value Euro 0.01 per share | Mar 23, 2017 | S | 44,000,000 | $41.60 | D | 25,750,000 | I | By Subsidiaries |
Table II — derivative securities
Remarks
The Ordinary Shares of Mylan N.V. (''Mylan'') described in this report are held directly by Abbott Products and Abbott Investments Luxembourg S.a r.l (collectively, the ''Subsidiaries''). Each of the Subsidiaries is an indirect, wholly-owned subsidiary of Abbott Laboratories (''Abbott''). In Abbott's capacity as the ultimate corporate parent of the Subsidiaries, Abbott may be deemed to indirectly beneficially own such Ordinary Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. The reported sale price does not include discounts and commissions. As a result of the reported sale transaction, Abbott and the Subsidiaries are no longer subject to the reporting requirements of Section 16 with respect to their beneficial ownership of Mylan Ordinary Shares.